Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.

OK
MENU
Back to Top

New IPA Webinar Announced: Treatment of Personality Disorders in Later Life

IPA

REGISTER NOW FOR OUR UPCOMING EVENT

Wednesday, 28 May at 5:00 AM CST (US/Canada)

Treatment of Personality Disorders in Later Life

Optimizing assessment of personality pathology in older adults by dimensional approaches.
- Prof. Dr. Gina Rossi

Treatment of Personality Disorders in Later Life
- Prof. Dr. Bas van Alphen

Discover a fresh approach to understanding and treating personality disorders in older adults in this exciting session! Traditional methods often overlook the unique changes that come with aging, but newer models like the DSM-5-TR Alternative Model and ICD-11 offer more personalized, flexible ways to assess and treat these conditions. These models focus on the severity of traits rather than fitting people into rigid categories, giving a clearer view of how personality evolves. We'll also explore how the clinical staging model helps track changes over time and guide better, more tailored treatments. Don’t miss this chance to learn how these new approaches can lead to more accurate diagnoses and better care for older adults with personality disorders!

Presenter: Dr. Bas van Alphen

Bas van Alphen is head of the Clinical Center of Excellence for Older Adults with Personality Disorders, Mondriaan mental health center, Heerlen-Maastricht, The Netherlands. In addition, he is endowed professor of clinical geropsychology at Vrije Universiteit Brussel (VUB). He obtained his PhD in 2006 at Radboud University Nijmegen on assessment of personality disorders in older adults. His scientific areas of interest, in addition to personality disorders, are in particular autism spectrum disorders, addiction and (complex) PTSD in older adults. He also provides national and international education to psychologists, psychiatrists and clinical geriatricians, such as for the European Association of Geriatric Psychiatry. Recently he is editor-in-chief of the Dutch scientific journal (Journal of Geropsychology) and he is chair of the Dutch consortium of clinical geropsychology.

Presenter: Prof. Dr. Gina Rossi

Gina Rossi is professor at the Vrije Universiteit Brussel (VUB),  and head of the VUB Personality and Psychopathology research group. Her major research line focuses on conceptualization, assessment and treatment of personality disorders across the adult life span and she is specialized in geropsychology. She promotes a Research and Teaching Chair “Clinical Geropsychology” (Mondriaan Netherlands – VUB), chairs the VUB-UG Research Alliance group “Psychopathology and Information Processing in Older Adults” and co-promotes the Interdisciplinary Research Program “Gerontopole Brussels”. An overview of her publications can be found on ‪Gina Rossi - ‪Google Scholar

CLICK HERE TO REGISTER NOW

IPA Webinar Series, Program Organizers:

Prof Myrra Vernooij-Dassen, PhD
Radboud University

Nijmegen Medical Centre
Chair, IPA Webinar Task Force
The Netherlands
Robert Madan MD FRCPC
Deputy Chief of Staff, Baycrest,
Canada

Prof Maria I. Lapid, MD
Professor of Psychiatry
Mayo Clinic,
United States


Up Coming International Learning Opportunities:

Please join us Friday May 16 at 8 am Eastern Time for the next International Geriatric Mental Health Education Network Virtual Rounds: Anticholinergic Medications and their Effects on Aging Minds: A Risk We Can’t Ignore.

Presenter:
Dr. Susmita Chandramouleeshwaran
Assistant Professor, Department of Psychiatry
University of Ottawa
Staff Geriatric Psychiatrist, The Ottawa Hospital|
Clinical Investigator, Clinical Epidemiology Program
Ottawa Hospital Research Institute, University of Ottawa

Learning Objectives:
- Identify medications with strong anticholinergic properties and their potential to contribute to cognitive impairment.
- Evaluate the cumulative anticholinergic burden in older patients using validated tools.
- Apply deprescribing strategies and shared decision-making approaches to minimize anticholinergic-related cognitive decline in clinical practice.

 Click here to register!

Acknowledgements

Acadia Pharmaceuticals Axsome Lundbeck Otsuka